Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical Industries showcases a robust financial performance, with its generics segment projected to contribute $9.5 billion in global sales for 2024, representing 57% of the company's total sales, an increase from 55% in 2023. Additionally, the company's international presence is strengthening, evidenced by a 5.3% year-over-year growth in ex-US sales, compared to 4% growth in US sales, and expanding product offerings such as Ajovy in over six countries and Austedo in China, Israel, and Brazil. Furthermore, European sales account for 31% of the overall revenue, while international sales have risen to 15%, up from 13% in 2022, highlighting a diverse and growing market reach.

Teva Pharmaceutical Industries has experienced significant challenges, particularly in its US sales, where affected products now contribute only 4% to total US sales in 2024, despite a slight increase from 2023. Additionally, the company's active pharmaceutical ingredient (API) segment reported a notable 16% decline in third-party sales in 2023, highlighting potential issues related to generic oversupply and margin erosion, despite an overall 6% increase in total sales. Furthermore, Teva's generic sales in the US have declined by 13% year-over-year for the quarter, indicating persistent difficulties in maintaining its market position.